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Abstract
Autonomic nervous system dysfunction observed in fibromyalgia,
characterized without exception by a sympathetic hyperactivity and
hyporeactivity, has been reported. However, several studies
demonstrated reduced levels of norepinephrine and neuropeptide
Y at rest and after tilt table in some patients, which was improved
by beta-stimulating agents. These findings support heterogeneity in
fibromyalgia-associated dysautonomia. Fibromyalgia could be a
generalized sympathetic dystrophy since both conditions are
activated by trauma and partly linked to sympathetic mechanisms.
Yet they differ on several points: hormonal and neurochemical
abnormalities are observed in fibromyalgia whereas activation by
peripheral trauma and hyperosteolysis are observed in reflex
sympathetic dystrophy.
In a well documented review on the stress response system,
Martinez-Lavin [1] proposes an original approach to dysauto-
nomia, fibromyalgia syndrome (FMS) and reflex sympathetic
dystrophy (RSD). Several points are probably oversimplified
and deserve some comments, based on two questions: is the
autonomic nervous system dysfunction observed in FMS the
same for all patients? And is fibromyalgia a generalized
sympathetic dystrophy?
Is the autonomic nervous system dysfunction
observed in FMS the same for all patients?
Martinez-Lavin [1] reports “an exaggerated sympathetic
activity […] described without exception […] in women”,
associated with a “deficient sympathetic response to different
types of stressors” and abnormalities of the gene encoding
catechol-O-methyl transferase in FMS. This “hyperactivity”
associated with “hyporeactivity” seems to be improved by
pindolol or by “sympatholytic maneuvers”.
However, Russell [2] reported in 1993 that “some patients
exhibited substantially elevated norepinephrine levels but the
mean values for epinephrine and norepinephrine were not
significantly different from controls.” Several patients had
reduced levels, as confirmed by the author (IJ Russell,
personnal communication), who concluded that “the relevance
of this apparent heterogeneity in norepinephrine levels is not
yet known.”
Similarly, Crofford [3], referring to two studies [4,5], reported
that “Neuropeptide Y (NPY) co-localizes with norepinephrine
in the sympathetic nervous system […] elevated plasma NPY
levels are seen with […] strong sympathetic activation.
Patients with FMS have significantly lower plasma NPY levels
than matched control subjects. These findings have been
confirmed by Clauw et al. who demonstrated significantly
lower basal NPY levels in FMS patients compared with
controls as well as low NPY levels after 30 minutes on tilt
table.” It is noteworthy that another paper on heart rate
variability by Clauw and colleagues [6] suggested a
“diminished sympathetic activity” in patients with FMS and
chronic fatigue syndrome. Recently, Bennett [7] confronted
the data suggesting that FMS patients have an increased
sympathetic tone with “an inverse association between pain
sensitivity and blood pressure” and considered polymorphism
of the gene encoding catechol-O-methyl transferase as only a
part of the fibromyalgia genetic diversity.
With respect to specific treatments, pindolol, as discussed by
Martinez-Lavin, is a non-selective β-blocking agent that pos-
sesses an intrinsic sympatho-mimetic activity. It exerts effects
like epinephrine or isoproterenol and its efficiency may be
similar to that of the β-stimulating agent salbutamol in FMS [8].
With regard to these data, the concept of two subgroups of
patients as proposed by Russell in 1993 [2] and
characterized by decreased or increased sympathetic activity
and norepinephrine levels could enable Martinez-Lavin’s
approach to co-exist with that of Clauw and Crofford, whereas
the ‘no exception’ rule, which complicates the already
problematic diagnosis of FMS, could be amended.
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Is fibromyalgia a generalized sympathetic
dystrophy?
RSD is a poorly defined condition in spite of ‘new’ but still
unclear concepts such as complex regional pain syndrome
type I (RSD) and type II (causalgia).
Sympathetic dysfunction has been partly involved in patho-
physiological mechanisms of FMS and RSD but, if both
conditions “affect mostly females and have frequent post-
traumatic onset” [1], they exhibit more differences than
similarities.
Even if controversial findings have been reported on fibro-
myalgia traumatic triggering factors [9], FMS occurrence is
not unusual after whiplash injury. FMS is associated with
subtle and diverse hormonal disorders [3], energy
metabolism impairment as well as neurochemical abnor-
malities, such as elevated cerebrospinal fluid levels of nerve
growth factor [2,7]. All these findings are less frequent and
less marked in RSD [10] and nerve growth factor is probably
increased in complex regional syndrome type II only [11].
RSD is usually observed after peripheral trauma and is
perpetuated by a biphasic evolution, with a ‘warm’ period
(biological, X-rays and isotopic findings support increased
osteolysis [12]) often followed by a ‘cold’ period associated
with trophic disorders. Spectacular improvements are
sometimes reported after antiosteolytic treatment, such as
biphosphonates. None of these findings is observed in fibro-
myalgia and the only common treatment could be calcitonin
[12] and probably some antidepressants (with higher dosages
in RSD).
The links between sympathetic activity and RSD have been
recently reviewed by Pham and Lafforgue [10], who report
that “findings suggest a decreased sympathetic tone,
reduced level of norepinephrine and neuropeptide Y in the
affected limb…” whereas “there is a hyper reactivity to
catecholamines associated with increased adrenoceptors…”
Similarly, Berthelot and colleagues [11] consider that “the
pathogenic role of adrenergic sympathetic activity has been
successfully challenged” in this condition and that “any
reference to the sympathetic system is inappropriate”.
Conclusion
All these findings do not support a particular link between
FMS and RSD; they suggest probable heterogeneity of
dysautonomia features in FMS and could define subgroups of
patients and, therefore, improve therapeutic approaches.
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